BMY Jan 2025 28.000 call

OPR - OPR Delayed Price. Currency in USD

Add to watchlist

13.08

0.00

(0.00%)

As of 11:28AM EDT. Market open.

Loading interactive chart...

Business Wire
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer
PRINCETON, N.J., June 01, 2024--KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced....
Zacks
Bristol Myers (BMY) Gets EC Nod for Opdivo Label Expansion
Bristol Myers' (BMY) Opdivo combination regimen receives the European Commission's approval for the first-line treatment of unresectable or metastatic urothelial carcinoma.
Zacks
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.